Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy

Cancer Journal from Scientific American

Volumn 2, Issue 3, 1996, Pages 166-174

  Dahlborg, Suellen A ^a   Henner, W David ^b   Crossen, John R ^c   Tableman, Mara ^d   Petrillo, Annie ^a   Braziel, Rita ^a   Neuwelt, Edward A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND STATE UNIVERSITY   (United States)

Author keywords

Central nervous system; Cytoxan; Lymphoma; Methotrexate

Indexed keywords

ANTINEOPLASTIC AGENT; MANNITOL; OSMOTIC DIURETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; BLOOD BRAIN BARRIER; BRAIN TUMOR; CHILD; CLINICAL TRIAL; COGNITION; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEUROPSYCHOLOGICAL TEST; OSMOSIS; PRESCHOOL CHILD; PROGNOSIS; RADIOTHERAPY; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COGNITION; COMBINED MODALITY THERAPY; DIURETICS, OSMOTIC; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MANNITOL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OSMOSIS; PROGNOSIS; RADIOTHERAPY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0001613639     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma. Neurology 1996;46:435-439.
2. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-1104.
3. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma: the Massachusetts General Hospital experience 1958-1989. Cancer 1994;74:1383-1397.
4. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972;34:187-220.
5. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospecrive trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992;23:9-17.
6. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994;12:627-642.
7. Goffman TE, Glatstein E. CNS lymphoma: back to the drawing board. Int J Radiat Oncol Biol Phys 1992;23:247-248.
8. Glass J, Gruber M, Cher L, Hochberg F. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994;81:188-195.
9. Armitage AJJ. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993;328:1023-1030.
10. Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1994;27:1356-1361.
11. Neuwelt EA, Williams PC, Mickey BE, Frenkel EP, Henner WD. Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption. Pediatr Neurosurg 1994;21:16-22.
12. Lee Y, Bruner JM, Van Tassel P, Libshitz HI. Primary central nervous system lymphoma: CT and pathologic correlation. AJNR Am J Neuroradiol 1986;7:599-604.
13. Neuwelt EA, Frenkel EP, Gumerlock MK, Braziel R, Dana B, Hill SA. Developments in the diagnosis and treatment of primary CNS lymphoma: a prospective series. Cancer 1986;58:1609-1620.
14. Neuwelt EA, Goldman D, Dahlborg SA et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;1580-1590.
15. Neuwelt EA, Balaban E, Diehl J, Hill S, Frenkel E. Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. Neurosurgery 1983;12:662-671.
16. Roman-Goldstein S, Mitchell P, Crossen JR, Williams PC, Neuwelt EA. MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. AJNR Am J Neuroradiol 1995;16:543-553.
17. Crossen JR, Goldman DL, Dahlborg SA, Neuwelt EA. Neuropsychological assessment outcomes of non-AIDS primary central nervous system lymphoma patients before and after blood-brain barrier disruption chemotherapy. Neurosurgery 1992;30:23-29.
18. Thorndike RL, Hagen EO, Sader JM. Stanford Binet Intelligence Scale. 4th ed. Chicago: Riverside Publishing, 1986.
19. Adams W, Sheslow D. Wide Range Assessment of Memory and Learning. Wilmington, Del: Tastak Assoc, 1990.
20. Russell EW. A reference scan method for constructing neuropsychological test batteries. J Clin Exp Neuropsychol 1987;9:376-392.
21. Janssen RS, Saykin AJ et al. Neurological and neuropsychological manifestations of HIV-1 infection: association with AIDS-related complex but not asymptomatic HIV-1 infection. Ann Neurol 1989;26:592-600.
22. McArthur JC, Cohen BA, Seines OA et al. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1-infected individuals: results from the Multicenter AIDS Cohort Study. Ann Neurol 1989;26:601-611.
23. Miller EN, Selnew OA, McArthur JC et al. Neuropsychological performance in HIV-1-infected homosexual men: the multicenter AIDS Cohort Study (MACS). Neurology 1990;40:197-203.
24. Wilkie FL, Eisdorfer C, Morgan R, Loewenstein DA, Szapocznik J. Cognition in early human immunodeficiency virus infection. Arch Neurol 1990;47:433-440.
25. Lawless JF. Statistical Models and Methods for Life-time Data. New York, NY, Wiley, 1982.
26. Sokol RR, Roliff FJ. Biometry, 2nd ed. New York: W.H. Freeman, 1980.
27. Millay RH, Shults WT, Neuwelt EA, Hill SA, Klein ML. Maculopathy associated with combination chemotherapy and osmotic blood-brain barrier opening. Am J Ophthalmol 1986;102:626-632.
28. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms, a retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78:767-775.
29. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78:762-766.
30. Walker RW, Posner JB. Central nervous system neoplasms. Curr Neurol 1984;5:285-320.
31. Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high grade astrocytomas in adults. J Neurosurg 1990;73:331-344.
32. Carton GR, Schomberg PJ, Scheithauer BW, Shaw EG, Ilstrup DM, Blackwell CR. Medulloblastoma-prognostic factors and outcome of treatment: review of the Mayo Clinic experience. Mayo Clin Proc 1990;65:1077-1086.
33. Neuwelt EA, O'Neill OR, Roman-Goldstein S, Shults T. Clinical features and imaging of pineal region tumors. In: The practice of Neurosurgery. 1996, in press. Baltimore: Williams and Wilkins, Tindall, Cooper, Barrow eds.
34. Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HWK. Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 1994;80:247-253.
35. Eby NL, Grufferman S, Flannelly CM, Schold SC, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer 1988;62:2461-2465.
36. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988;68:835-853.
37. Peterson K, Gordon KB, Heinemann MH, DeAngelis LM. The clinical spectrum of ocular lymphoma. Cancer 1993;72:843-849.
38. Tomlinson FH, Kurtin PJ, Suman VJ et al. Primary intracerebral malignant lymphoma: a clinicopathologic study of 89 patients. J Neurosurg 1995;82:558-566.
39. Remick SC, Diamond C, Migliozzi JA. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome: a retrospective analysis and review of the literature. Medicine 1990;69:345-360.
40. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-643.
41. Neuwelt EA. Blood-brain barrier disruption in the treatment of brain rumors: clinical implications. In: Neuwelt EA (ed.) Implications of the Blood-Brain Barrier and Its Manipulation. Vol. 2. Clinical Implications, New York: Plenum Press, 1989;195-262.